M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Despite considerable progress in the management of major risk factors over recent decades, cardiovascular diseases (CVD) attributable to atherosclerosis are still a predominant cause of death worldwide. This is due, in large part, to the expansion of risk factors related to obesity such as insulin resistance and diabetes 1 . In fact, the risk of developing CVD in adults with diabetes is two to four times higher than in those without diabetes. Moreover, it is well established that insulin resistance and hyperglycemia promote atherosclerosis, leading to coronary artery disease. Yet the underlying mechanisms linking diabetes and atherosclerosis are still not completely understood. To overcome this lack of understanding, numerous studies have been conducted, using mouse models with targeted deletion in intimal cells, to evaluate the impact of impaired insulin signaling at the level of the arterial wall on atherosclerosis development and progression 2 . Taken together, this work highlights the critical consequences of altered insulin signaling, in both macrophages and endothelial cells, in atherogenesis and the formation of advanced plaques. In humans, comparative analyses of atherosclerotic plaques from diabetic and non-diabetic individuals have revealed some important differences in the quality and composition of plaques between these groups. Lesions from diabetic patients are characterized by a larger necrotic core, increased inflammation, neovascularization, intraplaque hemorrhage, and calcification [3] [4] [5] [6] [7] . Higher macrophage and T-cell content, along with increased proportions of apoptotic macrophages and smooth muscle cells, may contribute to this larger necrotic area 4, 8 . When combined with the increased prevalence of thin-cap fibroatheroma and fibrocalcific atheroma, observed using Virtual Histology intravascular ultrasound in vessels of diabetic patients 5 , these alterations of plaque morphology may explain the higher risk of acute coronary syndrome in diabetic patients. Indeed, coronary lesions of patients with diabetes mellitus are more vulnerable to rupture and subsequent thrombosis 3, 6 .
Thorough analyses of human plaque composition are a powerful means to uncover molecular mechanisms involved in plaque disruption and thrombosis leading to acute coronary events in diabetic individuals. Previous analyses of diabetic atherosclerotic lesions revealed a higher area of lipid-rich atheroma than in specimens from patients without diabetes 3, 8 . Lipid composition is a critical determinant of plaque instability, as it is well established that plaques exhibiting increased lipid content, which is positively associated with macrophage accumulation, are more prone to plaque rupture 9 . Although free cholesterol (FC) and cholesterol esters (CE) account for the majority of lipids in human atherosclerotic lesions 10, 11 , the recent development of 'omic' approaches, especially lipidomic analyses, now allow quantification of large sets of lipid species. Recent analyses of lipid species in human endarterectomy specimens by shotgun lipidomics resulted in the detection of 24 lipid species and the establishment of signature lipid profiles for vulnerable and stable plaques 10 .
Interestingly polyunsaturated fatty acids (PUFA)-containing lipid species were detected in excess in human atherosclerotic lesions versus normal human specimens 10, 12 , contributing to the lipid signature for vulnerable plaques 10 .
In this issue of Atherosclerosis, Ménégaut et al. 13 performed a unique, targeted lipidomic analysis of human atherosclerotic lesions focused on PUFA-containing lipid species in both diabetic and non-diabetic patients, in order to identify specific lipid species which characterized diabetic . Whether accumulation or generation of this specie within the plaque, versus its exclusion to plasma, is associated with lesion progression in diabetes is an intriguing possibility.
The striking increase in 2-AA-LPC in plaques from diabetic subjects observed by Ménégaut et al. 13 very likely resulted from local hydrolysis of diacyl-PC. A search for enzymes with phospholipase A1 activity which could be responsible for production of 2-AA-LPC in diabetic plaques led the authors to propose endothelial lipase (EL) and calcium-independent PLA 2 γ (iPLA 2 γ, PNPLA8) as potential candidates. Indeed, convincing immunohistochemistry experiments indicated that these two enzymes were expressed in plaques from diabetic subjects, and more precisely in plaque macrophages, with EL expression being significantly increased in diabetic lesions. EL has been reported to be highly expressed in macrophages in advanced human atherosclerotic lesions 17 and inhibition of its expression in human macrophages can attenuate proinflammatory cytokine expression and secretion 18 . However, the role of EL in atherosclerosis remains controversial, since Lipg deficiency in Apoe -/-mice fed a western diet has been shown to either increase susceptibility to atherosclerosis 19 or to have no effect on atherosclerosis development 20 . In humans, some LIPG variants have been associated with coronary artery disease 21 or microvascular complications in type 2 diabetic patients 22 .
Moreover, serum EL concentration is increased in type 2 diabetic patients, and is associated with subclinical inflammation 23 . Nonetheless, it must be kept in mind that EL catalyzes the hydrolysis of M A N U S C R I P T
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both PC and TG 24 , albeit with a higher specificity for PC, and exhibits both PLA1 and PLA2 activities 25 . It is therefore unlikely to be the only enzyme responsible for 2-AA-LPC production in atherosclerotic plaques. In contrast, iPLA 2 γ (PNPLA8) catalyzes the highly selective production of 2-AA-LPC 26 . Transgenic iPLA 2 γ mice are characterized by a marked increase of 2-AA-LPC production in mitochondria 26 , while iPLA 2 γ-deficient mice fed a western diet exhibit impaired mitochondrial oxidation of fatty acids and are resistant to obesity and insulin resistance 27 , highlighting the major role of iPLA 2 γ in maintaining optimal bioenergetic mitochondrial function. Although a growing body of evidence suggests that iPLA 2 γ could contribute to the pathophysiology of diabetes 27 and thrombosis 29 , the potential role of iPLA 2 γ in atherogenesis and acute coronary events is largely unknown and warrants further investigation. Given the evidence provided by Ménégaut et al. 13 , that iPLA 2 γ is expressed in human atherosclerotic lesions, and more specifically in plaque macrophages, there is strong rationale for generation of mouse models deficient in macrophage Pnpla8 to help elucidate the role of this lipase in atherosclerosis during diabetes.
The authors further found that plaque 2-AA-LPC was positively correlated with glycated hemoglobin levels and was associated with the presence of diabetes in multivariable logistic regression models 13 , providing important clues as to the molecular mechanisms of atherosclerosis progression in diabetes. While 2-AA-LPC content alone may not discriminate unstable versus stable plaques in diabetic patients, 2-AA-LPC is a key branch point metabolite in cellular eicosanoid PC, phosphatidylcholines.
